Background: In 2019, the WHO estimated that over 296 million people were living with chronic hepatitis B virus (HBV) infection and over 820,000 deaths attributable to hepatitis B. Most people living with HBV are unawa...Background: In 2019, the WHO estimated that over 296 million people were living with chronic hepatitis B virus (HBV) infection and over 820,000 deaths attributable to hepatitis B. Most people living with HBV are unaware of their immune status and live in endemic areas. This is the case of Benin and Senegal, which have little data on the disease. Objective: This study aimed to provide epidemiological furthers on hepatitis B in Dakar and Cotonou according to WHO recommendations about “obtaining data for action”. Materials and Methods: Our study took place at the Medical Biology Laboratory of the Idrissa Pouye General Hospital (LBM-HOGIP) in Dakar, Senegal. Participants were selected at the LBM-HOGIP of Dakar or at the LBMs of the health centres of the Archdiocese of Cotonou respectively from November to December 2019 and February to March 2020. All participants were tested for hepatitis B virus antigen (HBsAg) using a microparticle chemiluminescence immunoassay assay. Other risk factors including blood transfusion, haemodialysis, tattooing, cultural or clan scarification, piercing, injecting drug use, unprotected sex and surgical procedures were also investigated. Informed consent was obtained from each participant. The study was approved by the ethics committees in Senegal and Benin. For the biological tests, Excel and IBM SPSS Statistics software were used for the analysis of the results. Results: A total of 470 participants were recruited including 234 in Cotonou and 236 in Dakar. The median age in Cotonou was 29 years with extremes of 10 and 65 years, and 38 years in Dakar with extremes of 6 and 93 years. The prevalence of HBsAg was 12.39% in Cotonou and 19.91% in Dakar. The most affected age groups were 20 - 29 in Dakar and 30 - 39 in Cotonou. Except for piercing, none of the other risk factors considered in our study were found to be associated with HBV transmission in our populations. Conclusion: Our study is hospital-based and revealed high prevalence of HBsAg. These prevalences were higher in men.展开更多
Background: According to WHO estimates, by 2022 over 296 million people are living with chronic hepatitis B virus (HBV) infection, and over 820,000 have died from complications. In sub-Saharan African countries such a...Background: According to WHO estimates, by 2022 over 296 million people are living with chronic hepatitis B virus (HBV) infection, and over 820,000 have died from complications. In sub-Saharan African countries such as Benin and Senegal, few research studies have addressed the issue of HBV immunization. Objective: The main objective of this study was to evaluate immunization against the hepatitis B virus in populations residing in Cotonou and Dakar by titrating anti-HBs antibodies (Ab) and detecting total anti-HBc immunoglobulins (Ig). Materials and Methods: This was a prospective, descriptive, analytical study of two West African populations recruited in Dakar at the Laboratory of Medical Biology (LBM) of the General Hospital Idrissa Pouye (HOGIP) and in Cotonou at the LBMs of the health centres of the Cotonou archdiocese. HBsAg-negative patients constituted our study population. The study took place in November-December 2019 for Dakar and February-March 2020 for Cotonou. Anti-HBs antibodies were tested and titrated. In the event of anti-HBs positivity, total anti-HBc was determined. A microparticle chemiluminescence immunoassay was used for marker determination. The detection threshold was 2.50 IU/L for anti-HBs. Excel and IBM SPSS Statistics software were used for data analysis. Subjects’ sociodemographic characteristics were collected using a questionnaire, as was knowledge of their vaccination status. The study was approved by the ethics committees in Benin and Senegal. Results: A total of 394 HBs antigen-negative participants were recruited: 205 in Cotonou and 189 in Dakar. The population was predominantly female, with 65.36% (N = 134) and 57.14% (N = 108) women in Cotonou and Dakar respectively. The median age of participants was 29 years in Cotonou, with extremes of 10 and 65 years, versus 39 years in Dakar, with extremes of 6 and 93 years. Some participants claimed to be unaware of their vaccination status: 33.17% in Cotonou and 56.61% in Dakar. The total prevalence of anti-HBs-positive subjects was 88.78% (N = 182) in Cotonou and 98.41% (N = 186) in Dakar. In Cotonou (N = 205), 35.61% (N = 73) of subjects had protective anti-HBs levels between 11.60 IU/L and 10,000 IU/L. In Dakar, 61.38% (N = 116) of subjects had protective HBV immunity, with anti-HBs titres ranging from 10.30 IU/L to 11357 IU/L. In Cotonou, 80.82% (N = 59) of immunized subjects (N = 73) had anti-HBC antibodies, compared with 84.48% (N = 98) of immunized individuals (N = 116) in the population recruited in Dakar, indicating immunization following HBV infection. Conclusion: Our study involved a predominantly female population, many of whom were unaware of their serological status. Vaccination policies and knowledge of the viral hepatitis B epidemic need to be strengthened.展开更多
文摘Background: In 2019, the WHO estimated that over 296 million people were living with chronic hepatitis B virus (HBV) infection and over 820,000 deaths attributable to hepatitis B. Most people living with HBV are unaware of their immune status and live in endemic areas. This is the case of Benin and Senegal, which have little data on the disease. Objective: This study aimed to provide epidemiological furthers on hepatitis B in Dakar and Cotonou according to WHO recommendations about “obtaining data for action”. Materials and Methods: Our study took place at the Medical Biology Laboratory of the Idrissa Pouye General Hospital (LBM-HOGIP) in Dakar, Senegal. Participants were selected at the LBM-HOGIP of Dakar or at the LBMs of the health centres of the Archdiocese of Cotonou respectively from November to December 2019 and February to March 2020. All participants were tested for hepatitis B virus antigen (HBsAg) using a microparticle chemiluminescence immunoassay assay. Other risk factors including blood transfusion, haemodialysis, tattooing, cultural or clan scarification, piercing, injecting drug use, unprotected sex and surgical procedures were also investigated. Informed consent was obtained from each participant. The study was approved by the ethics committees in Senegal and Benin. For the biological tests, Excel and IBM SPSS Statistics software were used for the analysis of the results. Results: A total of 470 participants were recruited including 234 in Cotonou and 236 in Dakar. The median age in Cotonou was 29 years with extremes of 10 and 65 years, and 38 years in Dakar with extremes of 6 and 93 years. The prevalence of HBsAg was 12.39% in Cotonou and 19.91% in Dakar. The most affected age groups were 20 - 29 in Dakar and 30 - 39 in Cotonou. Except for piercing, none of the other risk factors considered in our study were found to be associated with HBV transmission in our populations. Conclusion: Our study is hospital-based and revealed high prevalence of HBsAg. These prevalences were higher in men.
文摘Background: According to WHO estimates, by 2022 over 296 million people are living with chronic hepatitis B virus (HBV) infection, and over 820,000 have died from complications. In sub-Saharan African countries such as Benin and Senegal, few research studies have addressed the issue of HBV immunization. Objective: The main objective of this study was to evaluate immunization against the hepatitis B virus in populations residing in Cotonou and Dakar by titrating anti-HBs antibodies (Ab) and detecting total anti-HBc immunoglobulins (Ig). Materials and Methods: This was a prospective, descriptive, analytical study of two West African populations recruited in Dakar at the Laboratory of Medical Biology (LBM) of the General Hospital Idrissa Pouye (HOGIP) and in Cotonou at the LBMs of the health centres of the Cotonou archdiocese. HBsAg-negative patients constituted our study population. The study took place in November-December 2019 for Dakar and February-March 2020 for Cotonou. Anti-HBs antibodies were tested and titrated. In the event of anti-HBs positivity, total anti-HBc was determined. A microparticle chemiluminescence immunoassay was used for marker determination. The detection threshold was 2.50 IU/L for anti-HBs. Excel and IBM SPSS Statistics software were used for data analysis. Subjects’ sociodemographic characteristics were collected using a questionnaire, as was knowledge of their vaccination status. The study was approved by the ethics committees in Benin and Senegal. Results: A total of 394 HBs antigen-negative participants were recruited: 205 in Cotonou and 189 in Dakar. The population was predominantly female, with 65.36% (N = 134) and 57.14% (N = 108) women in Cotonou and Dakar respectively. The median age of participants was 29 years in Cotonou, with extremes of 10 and 65 years, versus 39 years in Dakar, with extremes of 6 and 93 years. Some participants claimed to be unaware of their vaccination status: 33.17% in Cotonou and 56.61% in Dakar. The total prevalence of anti-HBs-positive subjects was 88.78% (N = 182) in Cotonou and 98.41% (N = 186) in Dakar. In Cotonou (N = 205), 35.61% (N = 73) of subjects had protective anti-HBs levels between 11.60 IU/L and 10,000 IU/L. In Dakar, 61.38% (N = 116) of subjects had protective HBV immunity, with anti-HBs titres ranging from 10.30 IU/L to 11357 IU/L. In Cotonou, 80.82% (N = 59) of immunized subjects (N = 73) had anti-HBC antibodies, compared with 84.48% (N = 98) of immunized individuals (N = 116) in the population recruited in Dakar, indicating immunization following HBV infection. Conclusion: Our study involved a predominantly female population, many of whom were unaware of their serological status. Vaccination policies and knowledge of the viral hepatitis B epidemic need to be strengthened.
